Morgan Stanley Tyme Technologies, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Oct 27, 2022	BUY	$0.23 - $0.35 $6,051 - $9,208	26,311 Added 18.1%	171,708 $49,000
Q2 2022 Aug 15, 2022	BUY	$0.23 - $0.35 $6,051 - $9,208	26,311 Added 18.1%	171,708 $49,000
Q1 2022 Oct 27, 2022	SELL	$0.28 - $0.68 $7,367 - $17,891	-26,311 Reduced 15.32%	145,397 $51,000
Q1 2022 May 13, 2022	SELL	$0.28 - $0.68 $218,585 - $530,849	-780,661 Reduced 84.3%	145,397 $51,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.04 $465,010 - $806,018	775,018 Added 513.12%	926,058 $558,000
Q3 2021 Nov 15, 2021	BUY	$0.99 - $1.38 $149,529 - $208,435	151,040 New	151,040 $155,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.